Skip to main content

Advertisement

Table 4 Differences between iRECIST and iPERCIST classification, observed in 11/28 patients, in relation to survival

From: Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST

iRECIST iPERCIST Nb of patients Survival in days, mean (± SD)a
SD PMR 5 520 (± 104)
SD PMD 2 360 (± 234)
PD SMD 2 573 (± 204)
PR CMR 1 967
CR PMR 1 717
  1. iRECIST Immune RECIST, iPERCIST Immune PERCIST, SD Stable disease, PD progressive disease, PR partial response, CR complete response, PMR partial metabolic response, PMD progressive metabolic disease, SMD stable metabolic disease, CMR complete metabolic response
  2. aNB: mean survival for the population study (n = 28) = 479 days (± 248)